Today’s Stocks to Watch: M&A Moves and Powerplays

July 15, 2025

DENVER, Colo., Jul 15, 2025 (247marketnews.com)- Longevity Health (NASDAQ:XAGE) announced a definitive all-stock merger agreement with THPlasma, a rapidly scaling plasma collection company operating under the True Health brand. Simultaneously, Longevity confirmed the termination of its previously announced transaction with 20/20 BioLabs, as both parties mutually agreed to walk away.

This merger marks the third strategic deal for Longevity in two years, following its acquisitions of Carmell Therapeutics in July 2023 and Elevai Skincare in January 2025. Both of those companies focus on regenerative technologies; Carmell with plasma-derived growth factors and Elevai with exosomes sourced from human stem cells. With THPlasma, Longevity is now vertically integrating into plasma collection, a critical bottleneck in the supply chain for biologic and regenerative therapies.

The U.S. supplies more than 60% of the world’s plasma, yet demand continues to outpace collection, particularly for plasma-derived therapeutics like immunoglobulins, clotting factors, and albumin. THPlasma is poised to address that shortage head-on.

In a parallel narrative, Siyata Mobile (NASDAQ:SYTA) is nearing completion of a $185 million merger with Core Gaming, an AI-powered digital entertainment platform boasting 43 million monthly active users.

Core Gaming CEO Aitan Zacharin is expected to lead the combined company, with a 10% equity retention commitment to legacy Siyata shareholders. With an ambitious $100M revenue target for 2025 and a roadmap to profitability, this marks one of the boldest pivots on Nasdaq, from hardware communications to AI-driven media and gaming.

Kairos Pharma (NYSE:KAPA) today announced encouraging safety results from the ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC).

An interim safety analysis of the first ten patients enrolled in the study showed that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard-of-care apalutamide (a hormone therapy). Importantly, there were no dose-limiting toxicities or unexpected adverse events reported, and no Grade 3 or 4 toxicities observed to date. Treatment-related side effects were described as manageable with standard supportive care.

Brazil Potash (NYSE:GRO) entered a non-binding Memorandum of Understanding with Fictor Energia, the infrastructure arm of leading Brazilian private equity group Fictor Group. The agreement outlines a strategic partnership for the development of the power transmission infrastructure critical to the company’s flagship Autazes Potash Project.

The agreement calls on Fictor Energia to finance, develop, and operate the estimated $200 million power line that will connect the Autazes Project to Brazil’s electrical grid. The 102-mile (164-km) transmission line, which will supply 300MW of electricity, roughly 80% from renewable sources, is the only major external infrastructure required by the project. The line will be developed under a Build, Own, Transfer (BOT) model, with full ownership transferring to Brazil Potash after 25 years of operation.

In addition to infrastructure funding, Fictor Energia plans to invest $20 million in Brazil Potash equity: $2 million upon signing of the definitive agreement and $18 million following issuance of the installation license for the transmission line.

Polyrizon (NASDAQ:PLRZ) received notification from Nasdaq granting its request for the continued listing of its securities on the Nasdaq Capital Market.

Cyclacel (NASDAQ:CYCC) appears to be one of today’s top momemtum movers.

For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata-mobile-update/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (XAGE, SYTA, KAPA, GRO, PLRZ, CYCC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.